Immune Checkpoint Inhibitors: all 8,320 studies that test it

Page 2 of 84. Open to participants first (2,741), then studies with results posted, then the rest; newest registration first within each.

• A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
• Local and Systemic Immune Modulation by Rilvegostomig (AZD2936) in the Treatment of Advanced Gastric Cancer (RILVE Project)Not yet recruitingNCT07788664Phase 2
• Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07787273Phase 2
• Pemigatinib Plus PD-1 Inhibitor With or Without Chemotherapy in FGFR2 Fusion/Rearrangement-Positive CholangiocarcinomaRecruitingNCT07786766Phase 2
• Tailored Neoadjuvant Chemoimmunotherapy for Stage I TNBCNot yet recruitingNCT07786428Phase 2
• A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)RecruitingNCT07785609Phase 2
• QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingNCT07782840Phase 2
• Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.RecruitingNCT07781358Phase 2
• Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or CholangiocarcinomaRecruitingNCT07780838Phase 2
• Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal CancerNot yet recruitingNCT07780721Phase 2
• 16-Hour Fasting Plus Serplulimab and CAPEOX as Neoadjuvant Therapy in pMMR/MSS Advanced Mid-to-Low Rectal CancerNot yet recruitingNCT07779694Phase 2
• A Prospective Phase II Clinical Trial Evaluating the Efficacy and Safety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patients With Stage III Unresectable HER2-Positive NSCLCNot yet recruitingNCT07778745Phase 2
• Adebrelimab Combined With Dalpiciclib Isethionate Plus Chemotherapy for Neoadjuvant Treatment of Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07778732Phase 2
• TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07776717Phase 2
• Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCCNot yet recruitingNCT07776340Phase 2
• Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II TrialNot yet recruitingNCT07775040Phase 2
• Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular CarcinomaNot yet recruitingNCT07774247Phase 2
• Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast CancerNot yet recruitingNCT07772245Phase 2
• A Random, Non-controlled, Open Clinical Study of Apatinib Mesylate Combined With Albumin-bound Paclitaxel ± Adebrelimab in Treating Advanced Second-line Gastric CancerRecruitingNCT07770113Phase 2
• Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingNCT07770100Phase 2
• GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07768943Phase 2
• AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder CancerNot yet recruitingNCT07767994Phase 2
• Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingNCT07767266Phase 2
• Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07766889Phase 2
• Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic CholangiocarcinomaRecruitingNCT07766187Phase 2
• Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PCNot yet recruitingNCT07765836Phase 2
• Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract CancerNot yet recruitingNCT07765433Phase 2/3
• R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNCT07764601Not applicable
• Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular CarcinomaNot yet recruitingNCT07761286Phase 1/2
• DURATION-GC: FLOT Plus Durvalumab and TS-1 Plus Durvalumab for Resectable Gastric CancerNot yet recruitingNCT07757191Phase 2
• A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult ParticipantsRecruitingNCT07756645Phase 3
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2
• A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)Not yet recruitingNCT07753824Phase 2
• Personalized Neoantigen-pulsed Autologous Dendritic Cell Injections for Malignant Solid TumorsRecruitingNCT07752953Not applicable
• Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal CarcinomaNot yet recruitingNCT07752394Phase 2
• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual DiseaseRecruitingNCT07750158Phase 3
• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingNCT07750067Phase 2
• A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal CancerNot yet recruitingNCT07750041Phase 1/2
• A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid TumorsRecruitingNCT07749586Phase 1/2
• Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLCRecruitingNCT07748325Phase 2
• Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNot yet recruitingNCT07746388Phase 2
• Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With Metastatic Pancreatic CancerNot yet recruitingNCT07745790Phase 2
• SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell CarcinomaRecruitingNCT07744932Phase 2
• Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)RecruitingNCT07744698Phase 4
• A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)RecruitingNCT07743190Phase 2
• STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)Not yet recruitingNCT07743138Phase 2
• Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.Not yet recruitingNCT07742956Phase 2
• A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland CarcinomaNot yet recruitingNCT07740993Phase 2
• NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) MelanomaRecruitingNCT07740941Phase 2
• A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal CancerNot yet recruitingNCT07740720Phase 3
• A Study of DS-3939a in Participants With Solid TumorsNot yet recruitingNCT07739966Phase 1/2
• SKB264 Plus KL-A167 in MSI-H/dMMR Advanced Gynecological MalignanciesNot yet recruitingNCT07738757Phase 2
• Iparomlimab and Tuvonralimab (QL1706) Plus Lenvatinib and Chemotherapy for Extrapulmonary Neuroendocrine CarcinomaNot yet recruitingNCT07738159Phase 2
• Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionNot yet recruitingNCT07738055Not applicable
• To Explore a Single-arm Phase II Study on Intestinal Microbiota Transplantation Combined With Neoadjuvant Immunotherapy and Chemoradiotherapy for Locally Advanced Rectal Cancer Under MSS/pMMRNot yet recruitingNCT07738042Not applicable
• A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic CancerNot yet recruitingNCT07736612Phase 1/2
• RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal CancerRecruitingNCT07735624Phase 2
• Comparing ICI Followed By CCRT And CCRT Followed By Immunotherapy In Unresectable LA-ESCCRecruitingNCT07733830Phase 2
• Open-Label Neoadjuvant Pembrolizumab Plus Cetuximab in Betel Nut-Associated Locally Advanced Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07733466Phase 2
• A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCRecruitingNCT07733180Phase 2
• QL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract CancerRecruitingNCT07733115Phase 2
• RiMO-HNC-NEO1: Phase 2 Study of RiMO-301 and Hypofractionated Radiotherapy With Pembrolizumab for the Neoadjuvant Treatment of Resectable, Locally Advanced Head-Neck CancerNot yet recruitingNCT07732634Phase 2
• Neoadjuvant Short-course Hypofractionated Radiotherapy Plus Adebrelimab and Platinum Chemotherapy in Locally Advanced Cervical Cancer: A Single-arm Phase II TrialRecruitingNCT07731828Phase 2
• Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform StudyNot yet recruitingNCT07729917Phase 2
• FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
• Neoadjuvant Propranolol Plus SOX and Toripalimab for Locally Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingNCT07727993Phase 1/2
• Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 TrialRecruitingNCT07722754Phase 2
• An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingNCT07720284Phase 3
• A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECNot yet recruitingNCT07720193Phase 3
• Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNot yet recruitingNCT07720167Phase 2
• Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell CancerRecruitingNCT07718854Phase 2
• Immunotheray Combined With Simvastatin and Target Therapy and Chemotharepy for Advanced Colorectal CancerRecruitingNCT07718490Phase 2
• Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell CarcinomaNot yet recruitingNCT07715734Phase 2
• Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell Carcinoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical TrialNot yet recruitingNCT07715565Phase 2
• Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingNCT07714317Phase 1/2
• Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingNCT07713745Phase 2
• Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid Tumors With EGFR-PositiveRecruitingNCT07712029Phase 2
• Futibatinib (TAS-120) in Patients With Advanced Biliary Tract CancerRecruitingNCT07710885Phase 3
• Luvometinib in Combination With Serplulimab for NF2-Related TumorsNot yet recruitingNCT07708285Phase 1/2
• Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2
• Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Phase 2
• Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ AdenocarcinomaRecruitingNCT07700979Phase 3
• Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction AdenocarcinomaRecruitingNCT07699939Phase 2
• Toripalimab Combined With Beat Chemotherapy in the Treatment of Advanced Back-line Small Cell Lung CancerNot yet recruitingNCT07698054Phase 2
• SKB264 in Combination With SKB118 for Non-Small Cell Lung CancerRecruitingNCT07697586Phase 2
• EWSR1 Immunotherapy in Ewing Sarcoma and DSRCTNot yet recruitingNCT07695311Phase 1
• Trial of Therapies With IT cDC1s Combined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMDRecruitingNCT07694986Phase 2
• Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ AdenocarcinomaNot yet recruitingNCT07692334Phase 2
• A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction CancerRecruitingNCT07692204Phase 2
• Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell CarcinomaRecruitingNCT07692152Phase 3
• A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular CarcinomaNot yet recruitingNCT07691762Phase 3
• Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal CancerNot yet recruitingNCT07691632Phase 2
• Neoadjuvant HRS-4642 Plus Chemotherapy With or Without Immunotherapy for Pancreatic CancerNot yet recruitingNCT07691593Phase 2
• A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07691476Phase 2
• Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07689240Phase 3
• Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular CarcinomaRecruitingNCT07689175Phase 2
• Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2
• Sacituzumab Tirumotecan Plus Immunotherapy for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT07686588Phase 2
• HAIC + DEB-TACE + Toripalimab + Lenvatinib for Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07685535Phase 2

← Immune Checkpoint Inhibitors overview